

# Anthrax

## Epidemiology

### Source / Transmission

- **Spores in soil**, persist from years, no aerosolization, not a source for humans
- **Sick animals**: direct contact with lesions, meat consumption, spores on skin
- **Weaponized spores**:  $10^9$  to  $10^{12}$  spores/g, inhalation
- Humans are NOT infectious, internal mediastinum infection, no expelling bacilli, no secondary cases
- **Laboratory** exposure

**Incubation**  
1-7 days  
(max 60 days)


### INHALATION PHASE I

Fever, chills, headache, cough, dyspnea, chest pains, vomiting, abdominal pain  
Duration: few days,  
CXR: No pneumonia

NOT communicable

### INHALATION PHASE II

- Onset abrupt, fever, dyspnea, diaphoresis, shock
- Massive lymphadenopathy
- Hemorrhagic mediastinitis
- Hemorrhagic meningitis 50%
- Fulminant, death before dx
- Mortality: 90% no tx



### Differential:

- Aortic dissection
- Pulm. embolism

**Wide mediastinum in previously healthy with overwhelming ILI = anthrax**

### Toxins:

- Hemorrhage
- Edema
- Necrosis

### Bacillus anthracis

- Aerobic, gram-positive, spore-forming,
- nonmotile, non-hemolytic
- Large vegetative cell: 1-8  $\mu\text{m}$ /1-1.5  $\mu\text{m}$ , poor survival outside animal or human

### SKIN ANTHRAX

Through skin cut or abrasion on exposed skin area  
Spore germinate in skin  $\Rightarrow$  toxin

- Local edema
- Macule  $\Rightarrow$  vesicle  $\Rightarrow$  pustule  $\Rightarrow$  black eschar  $\Rightarrow$  falls off, no scar
- Lymphangitis + painful lymphadenitis
- Some systemic symptoms
- Antibiotic does not influence local lesion BUT prevents systemic sx
- Mortality 0% with antibiotics, 20% without

### GASTRO-INTESTINAL ANTHRAX

Ingestion of spores  
Oral /pharyngeal ulcer  $\Rightarrow$  edema, lymphadenopathy, sepsis

Lesions in terminal ileum and cecum:

- nausea, vomiting
- acute abdomen
- Sepsis, massive ascites
- Mortality high

## Diagnosis

- Gram stain of unspun blood, CSF: G+ boxcar
- Standard blood culture: 6-24 hrs confirmation in 12 hrs:  
1-Colonial morphology  
2-Hemolysis and motility: NON motile, NON hemolytic
- Rapid identification by ELISA for protective antigen
- PCR

### Differential bacteriology

- If not suspected peripheral lab will identify "Bacillus" and go no further
- Most "bacillus" = contamination or *B.cereus*
- Confirmation in specialized lab
- Sputum culture not useful: no pneumonia

## Treatment, Prophylaxis

Oral Rx	Initial Rx	Optimal if suscep	Duration
Adult	Cipro 500mg po q12h	Amoxicillin 500mg po q8hr	60 days
Child >20kg	Cipro 10-15mg/kg	Amoxicillin 500mg po q8hr	60 days
Child <20kg	Cipro 10-15mg/kg	Amoxicillin 15mg/kg po q12h	60 days
Pregnant	Cipro 500mg po q12h	Amoxicillin 500mg po q8hr	60 days
Immunosuppressed	same as other adult		

- Early antibiotics are essential
- Most natural strains sensitive to penicillin, doxycycline
- Some weaponized strains engineered to resist penicillin and doxycycline

## Control

Anyone w direct physical contact with anthrax should

- **Wash** exposed skin
- Remove then wash clothing with soap & water
- **Further decontamination** of directly exposed individuals **not indicated**
- Equipment /surfaces decontaminated with 5% hypochlorite (bleach) 30 mn / Steriplex <sup>®</sup>
- Receive **postexposure antibiotic prophylaxis** until the substance is proved not to be anthrax

### HCF: Standard Precautions

### HUMAN VACCINE

US anthrax vaccine = inactivated cell-free product, filtrate of a nonencapsulated attenuated strain

principal antigen = protective antigen  
licensed in 1970, Bioprot Corp., Lansing, MI  
6-dose series

all US military active- and reserve-duty personnel

1 small placebo-controlled human trial: efficacious against cutaneous anthrax

Population-wide vaccination not recommended

Postexposure vaccination following a biological attack with anthrax recommended with antibiotic administration to protect against residual retained spores, if vaccine were available